ArticleClinical ophthalmology (Auckland, N.Z.)2026
Design of a Pragmatic Randomized Controlled Trial for Comparing the Michigan Screening and Intervention for Glaucoma and Eye Health and Telemedicine Protocol with Usual Care for Disease Detection.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Purpose: To detail the methodology for the Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine Program Pragmatic Trial (MI-SIGHT 2) a follow-up to the original MI-SIGHT program that showed feasibility under ideal conditions and efficacy without a comparator. Patients and Methods: A pragmatic randomized controlled trial will compare rate of eye disease detected using the technology-based approach of the MI-SIGHT 2 program (intervention) vs standard optometric exam (control) in a Federally Qualified Health Center (FQHC) (n=900). Inclusion criteria are age ≥ 18 years and no acute eye symptoms. Exclusion criteria are pregnancy or cognitive impairment. The MI-SIGHT 2 intervention leverages technologies including autorefraction, pachymetry, optical coherence tomography, and external and fundus photography, in addition to care navigation support to access low-cost eyeglasses through an on-line retailer and support attendance at recommended follow-up. The primary outcome is detected eye disease as measured by an in-person optometrist exam (control) or by optometrist interpretation of the MI-SIGHT 2 technology-based protocol (intervention). The eye diseases targeted for detection include glaucoma/suspected glaucoma, visually significant cataract, and diabetic retinopathy. The secondary outcome is vision-related quality of life ascertained by survey six weeks after the initial study visit. The exploratory outcomes are program satisfaction and recommended follow-up completion. A cross-over design also will investigate within-person inconsistencies in diagnosis between arms by having participants undergo both screening approaches in randomized order. We will also determine accuracy of diagnoses by each protocol compared to a gold-standard diagnosis determined and adjudicated by glaucoma specialists. Two glaucoma specialist physicians will review all technology-based exams to assess the presence of eye diseases; a third glaucoma specialist physician will adjudicate when there is disagreement. Conclusion: This pragmatic trial will generate evidence to inform best practices for glaucoma and eye disease screening at community health centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.